Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
London, UK – 4th September 2024. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and...
-
New York, New York, Sept. 03, 2024 (GLOBE NEWSWIRE) -- DT Cloud Acquisition Corporation (Nasdaq: DYCQU, DYCQ, DYCQR) (the “Company”) today announced that it has entered into a non-binding letter of...
-
Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) -- The "Pharmaceutical Preparations Manufacturing in the UK - Industry Market Research Report" report has been added to ResearchAndMarkets.com's offering. ...
-
ZURICH, Aug. 29, 2024 (GLOBE NEWSWIRE) -- BC Platforms, a global leader in real world data, healthcare data management, and analytics, today announces the appointment of a new Chairperson of the...
-
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
LONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
-
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
-
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
-
LONDON and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
-
New York, United States , Aug. 20, 2024 (GLOBE NEWSWIRE) -- As per the Latest Report by Straits Research, the global organ-on-chip market size was valued at USD 52.53 million in 2023. It...
-
LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...